Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Turnstone Biologics Corp
Healthcare
P/NCAV
0.4x
Ticker
TSBX
Exchange
NASDAQ
Country
United States
Close
3.06 $
Mkt Cap
35.4M $
EV
17.6M $
NCAV Burn Rate
0%
Current Ratio
8.57
Debt/Equity
0.0
EV/REV
0.91x
EV/EBIT
-0.3x
EV/FCF
-0.3x
Dilution
-27.8% p.A
Total Net Income
-52.8M $
Cheapness
97.0%
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average